Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma
-
- Noda Teppei
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Komune Noritaka
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Yasumatsu Ryuji
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Akagi Tsuchihashi Nana
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Tamae Akihiro
- Department of Otolaryngology, Head and Neck Surgery, Hamanomachi Hospital
-
- Matsumoto Nozomu
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Sato Kuniaki
- Head and Neck section, National Kyushu Cancer Center
-
- Uchi Ryutaro
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Koike Kensuke
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Wakasaki Takahiro
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
-
- Tanaka Risa
- Department of Oncology, Hamanomachi Hospital
-
- Nakagawa Takashi
- Department of Otolaryngology, Head and Neck Surgery, Kyushu University Hospital
Bibliographic Information
- Other Title
-
- 再発・切除不能側頭骨扁平上皮癌に対するニボルマブの治療効果の検討
Search this article
Description
The immune checkpoint inhibitor Nivolumab was approved for the treatment of platinum-refractory head and neck squamous cell carcinoma (SCC), expanding the treatment options for recurrent or advanced head and neck SCC. However, since temporal bone squamous cell carcinoma (TB-SCC) is very rare cancer, the effectiveness of Nivolumab remains unclear. We investigated the effects of Nivolumab for TB-SCC.Chart information was collected for all patients who underwent the first administration of Nivolumab for recurrent or residual TB-SCC in our hospital between September 2017 and December 2019. Tumor staging followed the modified Pittsburgh classification. Changes in the tumor burden and survival outcome were examined.We examined 9 patients with recurrent or residual TB-SCC who started administration of Nivolumab. In these cases, recurrent or residual SCC was observed after chemotherapy and/or chemoradiotherapy including platinum. The duration of Nivolumab was 2-54 weeks (median 20.0 weeks). The evaluation of the therapeutic effect according to the RECIST method showed partial response in 1 case, stable disease in 2 cases, progressive disease in 4 cases, and size unevaluated in 2 case. Although the number of cases was small, comparing with 5 cases without Nivolumab, these cases showed longer overall survival (1-year OS 33.3% vs 20.0%).We used Nivolumab as palliative chemotherapy in 9 patients with recurrent/residual TB-SCC, and we were able to obtain a certain therapeutic effect on TB-SCC as well as other head and neck SCC.
Journal
-
- Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo)
-
Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 125 (5), 916-917, 2022-05-20
Japanese Society of Otorhinolaryngology-Head and Neck Surgery
